Panagora Asset Management’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.3M Buy
690,687
+425,740
+161% +$1.59M 0.01% 612
2026
Q2
$1.24M Buy
264,947
+178,187
+205% +$609K ﹤0.01% 711
2026
Q1
$228K Buy
+86,760
New +$204K ﹤0.01% 1057
2023
Q2
– Sell
-107,891
Closed -$339K – 1291
2023
Q1
$339K Buy
+107,891
New +$635K ﹤0.01% 1229

Other funds holding CCCC

Panagora Asset Management's CCCC Position: Q3 2026 in Review

Panagora Asset Management increased its C4 Therapeutics (CCCC) stake by 161% in Q3 2026, buying an estimated $1.59M and bringing the position to 690,687 shares worth $2.3M. The position accounts for 0.01% of the portfolio, ranked #612.

Panagora Asset Management first reported a position in CCCC in Q1 2023 and has held it in 4 quarters since. 146 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Panagora Asset Management held 690,687 shares of C4 Therapeutics worth $2.3M as of Q3 2026.
  • Panagora Asset Management bought 425,740 C4 Therapeutics shares in Q3 2026, an estimated $1.59M.
  • C4 Therapeutics made up 0.01% of Panagora Asset Management's portfolio in Q3 2026, its #612 holding.
  • Panagora Asset Management first reported a position in C4 Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • 146 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Panagora Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.